Advanced NanoBiomed Research

Advanced NanoBiomed Research is a fully open access journal published by Wiley-VCH in Weinheim, Germany, launched in 2021 as part of Wiley's Advanced portfolio, and devoted to cutting-edge research at the interface of engineering, biomedicine and translational science, with a 2025 Journal Impact Factor of 4.8.《先进纳米生物医学研究》（Advanced NanoBiomed Research）是（Wiley-VCH）在德国魏因海姆出版的完全开放获取期刊，2021 年创刊并隶属（Wiley）的（Advanced）系列，致力于发表工程学、生物医学与转化科学交叉前沿的研究，2025 年影响因子为 4.8。

Scope

• The journal positions itself at the interface of engineering, biomedicine and translational science, highlighting innovations that span nano, micro and macro scales and that advance preclinical discoveries toward clinical application in disease prevention, diagnosis and treatment.该刊定位于工程学、生物医学与转化科学的交叉前沿，突出跨越纳米、微米与宏观尺度的创新，并推动临床前发现走向疾病预防、诊断与治疗的临床应用。
• Advanced biomaterials form a core area, including hydrogels, two-dimensional materials, biopolymers, composites, biodegradable materials, biohybrids and biomimetics, together with antimicrobial surfaces and coatings.先进生物材料是核心方向之一，涵盖水凝胶、二维材料、生物聚合物、复合材料、可降解材料、生物杂化与仿生材料，以及抗菌表面与涂层。
• Nanomedicine topics cover drug, gene and nucleic acid delivery, nanotheranostics and multimodal imaging.纳米医学方向覆盖药物、基因与核酸递送、纳米诊疗学与多模态成像。
• Immunoengineering, synthetic biology and engineered microenvironments are equally in scope.免疫工程、合成生物学与工程化微环境同样属于收稿范围。
• Bioengineering and biofabrication span tissue and organ engineering, regenerative medicine, organoids, organs-on-chip, disease-on-chip, bio-MEMS and other micro-physiological systems, bioprinting, living materials, mechanobiology and cellular biomechanics.生物工程与生物制造方向涵盖组织与器官工程、再生医学、类器官、器官芯片、疾病芯片、（bio-MEMS）与其他微生理系统、生物打印、活体材料、力学生物学与细胞生物力学。
• Devices, sensors and smart health technologies include diagnostic devices, lab-on-a-chip and point-of-care platforms, wearables, implantable systems, medical robotics, biosensors and bioelectronics, neuromodulation and intelligent drug delivery systems, and AI-enabled connected health systems.器件、传感与智慧健康技术方向包括诊断器件、芯片实验室与即时检验平台、可穿戴设备、可植入系统、医疗机器人、生物传感器与生物电子、神经调控与智能药物递送系统，以及人工智能驱动的互联健康系统。
• Translational, preclinical and disease-focused research is strongly promoted, from cancer, cardiovascular, metabolic, infectious, immune-mediated and neurological disorders to biomarker discovery, controlled drug delivery and precision medicine.期刊大力推动转化、临床前与疾病导向研究，覆盖癌症、心血管、代谢性、感染性、免疫介导与神经系统疾病，以及生物标志物发现、可控药物递送与精准医学。

History

• Advanced NanoBiomed Research was launched in 2021 by Wiley-VCH, the Weinheim-based materials science publisher within John Wiley and Sons, with volume 1, issue 1 appearing that January.《先进纳米生物医学研究》于 2021 年由（Wiley-VCH）创办，该社是（John Wiley and Sons）旗下位于魏因海姆的材料科学出版机构，当年 1 月即出版第 1 卷第 1 期。^[1]
• The founding editorial set out a fully open access model and a scope reaching from traditional biomedicine, bioengineering and health-related materials science to precision medicine, nanomedicine and artificial-intelligence-driven health science.创刊社论阐明了完全开放获取模式，以及从传统生物医学、生物工程与健康相关材料科学，到精准医学、纳米医学与人工智能驱动健康科学的收稿范围。
• The journal has been online only since launch, carries the electronic ISSN 2699-9307, publishes under a CC BY licence and has no print edition.该刊自创刊起即为纯在线出版，电子刊号为 2699-9307，文章以（CC BY）许可发布，不设印刷版。
• It belongs to Wiley's Advanced portfolio, and a dedicated team of in-house editors applies the same standards and practices as for the other Advanced journals, supported at launch by an Executive Advisory Board and an International Advisory Board.该刊隶属（Wiley）的（Advanced）系列，专职内部编辑团队沿用其他（Advanced）期刊的标准与流程，创刊时并设有执行顾问委员会与国际顾问委员会。
• Twelve issues appear each year, and the journal is indexed in the Emerging Sources Citation Index, Scopus, DOAJ, CAS, INSPEC, COMPENDEX and Web of Science.该刊每年出版 12 期，并被（Emerging Sources Citation Index）、（Scopus）、（DOAJ）、（CAS）、（INSPEC）、（COMPENDEX）与（Web of Science）收录。
• In Journal Citation Reports the journal is placed in Q2 in Engineering, Biomedical, in Materials Science, Biomaterials and in Nanoscience and Nanotechnology, with a 2025 Journal Impact Factor of 4.8 against 4.4 in 2024.在（Journal Citation Reports）中，该刊在生物医学工程、材料科学（生物材料）与纳米科学与纳米技术三个类别均列（Q2），2025 年影响因子为 4.8，2024 年为 4.4。

Editors

• The Editor-in-Chief is Irem Bayindir-Buchhalter, an in-house editor at Wiley-VCH who has been with the journal since its founding team.现任主编为（Irem Bayindir-Buchhalter），她是（Wiley-VCH）的内部编辑，自创刊编辑团队起即在岗。
• She is supported by five Deputy Editors, Debarati Bandyopadhyay, Alanna Gannon, Swathi Lingam, Suchismita Saha and Tao Yang, all part of the in-house editorial team.她由五位副编辑协助，分别是（Debarati Bandyopadhyay）、（Alanna Gannon）、（Swathi Lingam）、（Suchismita Saha）与（Tao Yang），均属内部编辑团队。
• Manuscripts are handled by the in-house editors from submission through peer review to production, following the practices of the Advanced journals.稿件由内部编辑依（Advanced）期刊的惯例，自投稿经同行评审处理至出版。
• Submissions are made through Editorial Manager, and the editorial office can be reached at the journal address published on the Wiley page.投稿经（Editorial Manager）系统进行，编辑部联络方式见（Wiley）期刊页公布的地址。
• The journal reports an acceptance rate of about 46 per cent and a median of 29 days from submission to first decision.该刊公布的录用率约为 46%，自投稿至首次决定的中位时间为 29 天。
• An Editors' Choice collection showcases hand-picked papers, and the journal publishes research articles and reviews across its scope.期刊设有（Editors' Choice）精选合集展示编辑团队遴选的文章，并发表研究论文与综述。